Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current...
Guardado en:
Autores principales: | Pecenak J, Novotny V |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2c174cbcfa864d1aa3e1fa12daf2caec |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak J, et al.
Publicado: (2013) -
Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
por: Fornaro M, et al.
Publicado: (2013) -
Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Robert H Howland
Publicado: (2009) -
Quetiapine monotherapy for bipolar depression
por: Michael E Thase
Publicado: (2008) -
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman R, et al.
Publicado: (2011)